Close

Bristol-Myers Squibb (BMY) Announces New Data from Opdivo Phase 2 in cHL; ORR was 73% Across Subgroups

Go back to Bristol-Myers Squibb (BMY) Announces New Data from Opdivo Phase 2 in cHL; ORR was 73% Across Subgroups

New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

October 25, 2016 8:00 AM EDT

First presentation of Phase 2 CheckMate -205 cohort C data in classical Hodgkin lymphoma patients following treatment with autologous hematopoietic stem cell transplantation and brentuximab vedotin

After a median follow-up of 8.8 months, Opdivo demonstrated an objective response rate as assessed by an independent radiologic review committee of 73% overall and median progression-free survival of 11.2 months

The safety profile of Opdivo was consistent with previously reported data in this tumor type, and no new clinically meaningful safety signals were identified

PRINCETON, N.J.--(BUSINESS... More